Novartis Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).

1,375 total trials 110 currently recruiting 944 completed early-phase tilt top decile by trial count

Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.

Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.

Top-decile sponsor footprint

Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,375 total, page 10 of 28

COMPLETED Phase 2

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129
COMPLETED Phase 3

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
TERMINATED Phase 1

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

NCT03742349
TERMINATED Phase 3

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

NCT03626545
COMPLETED Phase 2

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

NCT03553823
COMPLETED Phase 1

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NCT03696771
COMPLETED Phase 2

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

NCT03647488
TERMINATED Phase 3

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

NCT03631199
COMPLETED Phase 3

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
COMPLETED Phase 2

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
TERMINATED Phase 3

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

NCT03629249
COMPLETED Phase 2

Study of Efficacy of PEAR-004 in Schizophrenia

NCT03751280
COMPLETED Phase 2

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
COMPLETED NA

Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)

NCT03887520
COMPLETED Phase 2

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
TERMINATED Phase 2

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

NCT03517566
COMPLETED Phase 2

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

NCT03568461
COMPLETED Phase 2

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

NCT03524612
TERMINATED Phase 3

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

NCT03710564
COMPLETED Phase 3

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

NCT03580356
COMPLETED Phase 3

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
COMPLETED Phase 1

Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

NCT03630159
COMPLETED Phase 2

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965
COMPLETED Phase 1

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

NCT03681457
COMPLETED Phase 2

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
COMPLETED Phase 2

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

NCT03517540
COMPLETED Phase 2

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT03484923
COMPLETED Phase 2

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

NCT03497897
COMPLETED Phase 3

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
COMPLETED Phase 3

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481634
COMPLETED Phase 3

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

NCT03512197
TERMINATED Phase 1

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
COMPLETED Phase 2

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

NCT03499899
COMPLETED Phase 3

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

NCT03504852
TERMINATED Phase 2

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

NCT03354754
TERMINATED Phase 1

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

NCT03400176
TERMINATED Phase 3

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

NCT03447769
COMPLETED Phase 4

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

NCT03350815
COMPLETED Phase 1

Safety Study of LLF580 in Obese Volunteers

NCT03466203
COMPLETED Phase 2

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

NCT03217422
COMPLETED

Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure

NCT03387163
TERMINATED Phase 2

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

NCT02939599
TERMINATED Phase 1

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT03301896
COMPLETED Phase 2

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791
COMPLETED Phase 3

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474
COMPLETED Phase 2

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

NCT02684058
COMPLETED Phase 2

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

NCT03338998
TERMINATED Phase 2

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

NCT03287414
COMPLETED Phase 2

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

NCT03264989
COMPLETED Phase 1

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

NCT03111992
← Previous Page 10 of 28 Next →

Phase Distribution

PhaseTrial count
Phase 1 326
Phase 2 450
Phase 3 393
Phase 4 77

Therapeutic Areas

Non-Small Cell Lung Cancer 10
Breast Cancer 9
Multiple Sclerosis 9
Chronic Spontaneous Urticaria 8
Hypertension 7
Melanoma 7
Relapsing Multiple Sclerosis 6
Carcinoma, Non-Small Cell Lung 6
Hidradenitis Suppurativa 5
Sickle Cell Disease 5

What is open in the Novartis Pharmaceuticals pipeline

110 recruiting of 1,375 indexed (8% open); 944 completed (69%).

Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).

Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Novartis Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Novartis PharmaceuticalsGlaxoSmithKlineEli Lilly and CompanyUniversity of PennsylvaniaUniversity of MichiganArcutis BiotherapeuticsMedtronic EndovascularPenumbraSK Life Science
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,375 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Novartis Pharmaceuticals page

1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.

  • 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.